Promotion and provision of colorectal cancer screening: a comparison of colorectal cancer control program grantees and nongrantees, 2011-2012. by Maxwell, Annette E et al.
UCLA
UCLA Previously Published Works
Title
Promotion and provision of colorectal cancer screening: a comparison of colorectal cancer 
control program grantees and nongrantees, 2011-2012.
Permalink
https://escholarship.org/uc/item/3rk0z5hw
Journal
Preventing chronic disease, 11(10)
ISSN
1545-1151
Authors
Maxwell, Annette E
Hannon, Peggy A
Escoffery, Cam
et al.
Publication Date
2014-10-02
DOI
10.5888/pcd11.140183
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
PREVENTING  CHRONIC  DISEASE
P U B L I C  H E A L T H  R E S E A R C H ,  P R A C T I C E ,  A N D  P O L I C Y 
  Volume 11, E170                                                                         OCTOBER 2014  
 
ORIGINAL RESEARCH
 
 
Promotion and Provision of Colorectal
Cancer Screening: A Comparison of
Colorectal Cancer Control Program
Grantees and Nongrantees, 2011–2012
 
Annette E. Maxwell, DrPH; Peggy A. Hannon, PhD; Cam Escoffery, PhD; Thuy Vu, MPH;
Marlana Kohn, MPH; Sally W. Vernon, PhD; Amy DeGroff, PhD 
 
Suggested  citation  for  this  article:  Maxwell AE,  Hannon PA,
Escoffery C, Vu T, Kohn M, Vernon SW, et al.  Promotion and
Provision  of  Colorectal  Cancer  Screening:  A  Comparison  of
Colorectal Cancer Control Program Grantees and Nongrantees,
2011–2012.  Prev  Chronic  Dis   2014;11:140183.  DOI:  http://
dx.doi.org/10.5888/pcd11.140183.
PEER REVIEWED
Abstract
Introduction
Since  2009,  the  Centers  for  Disease  Control  and  Prevention
(CDC) has awarded nearly $95 million to 29 states  and tribes
through the Colorectal Cancer Control Program (CRCCP) to fund
2 program components:  1)  providing colorectal  cancer  (CRC)
screening to uninsured and underinsured low-income adults and 2)
promoting population-wide CRC screening through evidence-
based interventions identified in the Guide to Community Prevent-
ive Services (Community Guide). CRCCP is a new model for dis-
seminating and promoting use of evidence-based interventions. If
the program proves successful, CDC may adopt the model for fu-
ture cancer control programs. The objective of our study was to
compare the colorectal cancer screening practices of recipients of
CRCCP funding  (grantees)  with  those  of  nonrecipients  (non-
grantees).
Methods
We conducted parallel Web-based surveys in 2012 with CRCCP
grantees (N = 29) and nongrantees (N = 24) to assess promotion
and provision of CRC screening, including the use of evidence-
based interventions.
Results
CRCCP grantees were significantly more likely than nongrantees
to use Community Guide-recommended evidence-based interven-
tions (mean, 3.14 interventions vs 1.25 interventions, P < .001)
and to use patient navigation services (eg, transportion or lan-
guage translation services) (72% vs 17%, P < .001) for promoting
CRC screening.  Both  groups  were  equally  likely  to  use  other
strategies.  CRCCP grantees  were  significantly  more  likely  to
provide CRC screening than were nongrantees (100% versus 50%,
P < .001).
Conclusion
Results suggest that CRCCP funding and support increases use of
evidence-based interventions to promote CRC screening, indicat-
ing  the  program’s  potential  to  increase  population-wide  CRC
screening rates.
Introduction
Colorectal cancer (CRC) is the second leading cause of cancer
deaths  among men and women in  the  United  States  (1).  CRC
screening reduces cancer deaths by detecting cancers at an early
stage and by detecting and removing precancerous polyps before
cancer develops (2). Screening is recommended for all adults aged
50 to 75 years (3). In 2012, 65.1% of adults in that age group met
CRC screening guidelines, and 27.7% of the population had never
been screened (4). People without health insurance or a regular
health care provider were more likely never to have been screened
(55% and 61%, respectively); however, a significant number with
health insurance and with regular health care providers also re-
mained unscreened (24% and 23.5%, respectively).
Studies suggest that most managers of cancer control programs are
aware of the evidence supporting the effectiveness of CRC screen-
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ing but are less familiar with research-tested (ie, evidence-based)
interventions to increase CRC screening (5,6). In 2009, the Cen-
ters  for  Disease  Control  and  Prevention  (CDC)  launched  the
Colorectal  Cancer Control Program (CRCCP), which provides
funding to 25 states and 4 tribes in the United States for 5 years.
The CRCCP’s goal is to increase CRC screening rates among men
and women aged 50 years or older in the funded states from its
2009 level of 64% to 80% by the end of 2014. CRCCP has 2 ob-
jectives. The first is to provide CRC screening to uninsured and
underinsured men and women aged 50 to 64. CRCCP grantees use
up to one-third of their funding to provide this screening. This ob-
jective is similar to that of CDC’s National Breast and Cervical
Cancer Early Detection Program, which provides comprehensive
cancer screening services to low-income, uninsured, and under-
insured women. CCRP’s second objective is to promote popula-
tion-wide CRC screening by using the evidence-based interven-
tions identified in the Guide to Community Preventive Services
(Community Guide, www.thecommunityguide.org). The interven-
tions are both client-oriented and provider-oriented. Client-ori-
ented  interventions  are  small  media  (flyers,  posters,  and  bro-
chures), client reminders, and efforts to reduce structural barriers
(eg, eliminating or simplifying administrative procedures; redu-
cing wait time or distance between service delivery settings and
target populations). Provider-oriented interventions are provider
reminders  and  provider  assessments,  and  feedback  (7–11).
CRCCP is the first CDC cancer screening program to encourage
grantees to use evidence-based interventions to promote screening
with the goal of having a population-level impact (12). CRCCP’s
approach is consistent with the Institute of Medicine’s call for the
engagement of multiple cross-sector partnerships between govern-
ment public health and the broader community to promote and
protect the public’s health (13).
CDC awarded CRCCP funds to 22 states and 4 tribal organiza-
tions in 2009 and funded 3 additional states in 2010. Over the first
4 years of the program, nearly $95 million was awarded to the
grantee organizations. In 2013, award size ranged from $362,205
to $1,050,000. The CRCCP represents a new model for dissemin-
ating evidence-based interventions and promoting their use while
also ensuring screening for a portion of the medically underserved.
If successful, CDC may adopt the model for future cancer control
programs. CDC is evaluating each aspect of the CRCCP, includ-
ing grantees’  methods of  providing screening and their  use of
evidence-based interventions to promote screening. The Cancer
Prevention and Control Research Network (14) is one of CDC’s
evaluation partners. Its mission is to accelerate the adoption of
evidence-based cancer prevention and control strategies in com-
munities. Studying whether and how the CRCCP model increases
use of evidence-based interventions to promote CRC screening fits
this mission. The Cancer Prevention and Control Research Net-
work designs and fields an annual grantee survey that measures
CRCCP grantees’ provision and promotion of screening.
Following the first grantee survey in 2011 (15), the evaluation
team expanded its 2012 survey to include a comparison group of
states and tribal organizations that did not receive CRCCP fund-
ing. This comparison group of states without CRCCP resources
could use other funding sources for CRC screening and promo-
tion, including the National Comprehensive Cancer Control Pro-
gram and state-specific cancer initiatives. The objective of our
study was to compare CRC screening provision and promotion
activities in states and tribes that received CRCCP funds with the
activities of states that did not receive funds. The purpose was to
assess whether the CRCCP funding model was associated with
grantee organizations’ greater use of evidence-based interventions
for promoting screening than their use by organizations that did
not receive CRCCP funding.
Methods
Using DatStat Illume (DatStat Corp), we administered parallel on-
line surveys to the 29 CRCCP grantees and to a comparison group
of 33 state and tribal grantees that had National Breast and Cer-
vical Cancer Early Detection Program funding but no CRCCP
funding. Respondents were asked to report any CRC prevention
and control activities. Both groups completed the surveys between
September 28 and December 10, 2012. Survey questions were
primarily closed-ended or Likert scale formatted, and they ad-
dressed CRC screening promotion and provision activities imple-
mented from July 2011 through June 2012.
The survey included questions on use of 5 evidence-based inter-
ventions identified in the Community Guide (ie, small media, cli-
ent reminders, reducing structural barriers, provider assessment
and feedback, and provider reminders), reasons for using those in-
terventions, and their ease of use. We also included questions to
assess use of other strategies, including patient navigation (eg,
transportation and language translation services), mass media, pro-
vider education, quality assurance and improvement activities,
group and one-on-one education, and client or provider incentives.
In regard to screening provision, the survey collected information
on the type of screening test primarily used, recruitment strategies,
and resources secured and partners enlisted for screening. The sur-
vey also included questions related to the use of patient naviga-
tion and to resources secured for cancer treatment. The University
of  Washington  institutional  review board  declared  the  survey
questionnaire and procedures exempt from review. Survey meth-
ods are more fully described by Hannon et al. (15). Descriptive
analyses were performed from 2013 through 2014 using SPSS ver-
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sion 19 (IBM Corp). We report results from 2 sample t tests for
continuous variables and χ2 tests and Fisher exact test for categor-
ical variables by using P < .01 as a more stringent standard to lim-
it the chances of spurious findings resulting from multiple compar-
isons. We also compared the practices of CRCCP grantee states
and nongrantee states before CRCCP funding by using informa-
tion from online sources and CDC reports to assess comparability
of the 2 groups. Parallel information was not available from tribal
organizations.
Results
All  CRCCP grantees (100%) and 24 of  33 nongrantees (73%)
completed the survey. Most respondents in both groups represen-
ted state health departments (77%) or tribal organizations (19%)
and  served  as  program directors  (51%)  or  program managers
(43%), with no significant differences between groups. Sixty-two
percent of all respondents had been involved in cancer control
work for more than 5 years, and 75% of respondents of organiza-
tions not CRCCP-funded reported being currently involved in pro-
moting and providing CRC screening.
All respondents in both groups had funding for the National Breast
and Cervical Cancer Early Detection Program and National Com-
prehensive Cancer Control Program and thus had a long history
(more than 20 years) in implementing breast and cervical cancer
screening and in conducting extensive cancer control planning.
CRCCP grantee states had significantly higher CRC screening
rates before program initiation, and comparison states had higher
levels of poverty and lack of insurance (Table 1 ). The 2 groups
did not differ at baseline with respect to other variables such as
population-based CRC screening programs or mandated insurance
coverage for CRC screening. Most nongrantees had applied for
CRCCP funding;  however,  actual  or  planned use of  evidence-
based interventions was neither a funding requirement nor an eval-
uation criterion that was considered in the application review and
ranking.
Screening promotion
CRCCP grantees were significantly more likely than nongrantees
to use Community Guide-recommended evidence-based interven-
tions to promote CRC screening (average of 3.14 vs 1.25 interven-
tions,  P < .001) (Table 2).  Most commonly used interventions
were small media (eg, flyers, posters, and brochures); client re-
minders (eg, postcards, letters or greeting cards, telephone calls,
text or e-mail messages); followed by efforts to reduce structural
barriers (eg, eliminating or simplifying administrative procedures
and other obstacles and reducing wait time or distance between
screening locations and target populations); provider assessment
and feedback at physician’s offices, provider groups, federally
qualified health centers, and other clinics; and provider reminders
in patient charts.
Primary reasons cited by CRCCP grantee organizations for using
Community Guide-recommended interventions to promote CRC
screening were that they were evidence-based (28% of responses),
were supported or promoted by CDC (12%), addressed an identi-
fied need (18%), and were easily implemented (12%). Primary
reasons for using Community Guide-recommended interventions
cited by nongrantees were that they were evidence-based (16% of
responses), addressed an identified need (17%), and were suppor-
ted  by  their  organizations  (15%).  CRCCP  grantees  and  non-
grantees similarly rated the ease or difficulty of implementing
Community Guide-recommended interventions. On a 5-point scale
(1= very difficult, 2 = somewhat difficult, 3 = neutral, 4 = some-
what  easy,  5 = very easy),  patient-directed interventions were
rated from 3.2 (reducing structural barriers) to 3.8 (small media),
and provider-directed interventions were rated from 3.1 (provider
assessment and feedback) to 3.5 (provider reminders) for all or-
ganizations combined.
Both CRCCP grantees and nongrantees implemented additional
strategies not currently recognized by the Community Guide to
promote CRC screening, including patient navigation, mass me-
dia, provider education, quality assurance and improvement activ-
ities, group and one-on-one education, and client or provider in-
centives. CRCCP grantees were significantly more likely to use
patient  navigation  to  promote  CRC screening  than  were  non-
grantees, either by their own staff or by reimbursing providers for
delivery of patient navigation services. Core navigation activities
routinely offered as part of screening promotion by both CRCCP
and nongrantees were educating patients about CRC screening
methods and bowel preparation, assessing and addressing barriers
to screening, scheduling CRC screening appointments, making re-
minder calls,  assisting with transportation, providing language
translation, providing child or elder care, identifying payment for
screening,  flagging  charts  for  medical  providers  to  promote
screening, and following up with patients about results and next
steps after screening. All other strategies were used to a similar ex-
tent by CRCCP and nongrantees.
Screening provision
CRCCP grantees were significantly more likely than nongrantees
to provide CRC screening (100% vs 50%, P < .001) (Table 3).
Among CRCCP grantees, about half provided colonoscopy (n =
13) or sigmoidoscopy (n = 1) as a primary screening test, and half
provided high-sensitivity guaiac fecal occult blood testing (n = 5)
or fecal immunochemical testing (n = 10). Among nongrantees
that provided screening (n = 12), 67% provided colonoscopy as
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the primary screening test and 33% provided fecal occult blood
testing. None of the nongrantees provided sigmoidoscopy or fecal
immunochemical testing as primary screening tests. Only 6 of the
24 unfunded sites (25%) reported receiving financial resources
specifically dedicated to support CRC screening, ranging from
$100,000 to $1,026,000 (median = $585,000). To deliver CRC
screening,  CRCCP  grantees  reported  more  partnerships  with
primary care clinics, endoscopy/gastrointestinal clinics, and feder-
ally  qualified  health  centers  than  did  nongrantees.  Both  were
equally likely to use patient navigators to support screening provi-
sion.
More CRCCP grantees than nongrantees engaged in patient re-
cruitment for screening through brochures, letters or other commu-
nication from health care providers, flyers and posters, and review
of patient records to identify patients eligible for screening. All
CRCCP grantees and 11 of the 12 non-grantees providing CRC
screening had secured treatment for anyone with a diagnosis of
cancer via their screening services through partners or resources
(eg, charity care at hospitals, cancer centers, individual doctors,
programs for indigent patients).
Discussion
Screening promotion
The CRCCP is a new and innovative public health model that uses
evidence-based interventions to promote CRC screening at the
population level and, consequently, serves as a natural experiment
to allow us to study the adoption of evidence-based interventions
that are encouraged by a funder. Our results have implications
beyond the CRCCP, because more and more funders are encour-
aging or requiring the use of evidence-based interventions (16).
Our comparison of CRCCP grantees and nongrantees suggests that
the CRCCP funding model may successfully promote the imple-
mentation  of  evidence-based  interventions.  CRCCP  grantees
quickly adopted this new model, which is different from the ap-
proach used in the National Breast and Cervical Cancer Early De-
tection Program, which is to provide screening only and not to
promote  screening.  Compared  with  nongrantee  organizations,
CRCCP grantees  were  significantly  more  likely  to  implement
evidence-based interventions that the CDC’s CRCCP recommen-
ded. Specifically, CRCCP grantees were twice as likely as non-
grantees to use small media and 3 to 4 times more likely to use cli-
ent reminders to increase community awareness of CRC screen-
ing  guidelines  and  to  increase  community  demand  for  CRC
screening. The frequent use of small media and client reminders
may be due to their ease of implementation and the fact that the
CRCCP grantees are able to take the lead on the implementation
of these activities (15). Fewer grantees used interventions directed
at health care providers, such as provider assessment and feed-
back and provider reminders, which usually require collaboration
with a partner organization. Although 2 to 3 times more CRCCP
grantees than nongrantees used provider-oriented interventions,
use could perhaps be increased by providing technical assistance
on how to implement these interventions.
For the most part, both groups were equally likely to implement
strategies not currently recognized by the Community Guide, such
as professional development and quality assurance and improve-
ment; these activities are components of the National Breast and
Cervical Cancer Early Detection Program and contribute to high-
quality screening and adherence to screening guidelines.  Both
CRCCP grantees and nongrantees frequently used patient navigat-
ors for both promoting and providing screening. Although patient
navigation has not been reviewed as a unique intervention by the
Community Guide and is  therefore not one of the Community
Guide-recommended evidence-based interventions, an increasing
number of studies suggest that patient navigation is a useful way
to promote CRC screening overall and among minority groups
(17–19).  Another  strategy  that  was  frequently  used  by  both
CRCCP and nongrantees was mass media such as television, ra-
dio, newspapers and billboards. Using funds for mass media pro-
motion can be costly and is cause for concern. A recent review of
studies examining the effect of mass media on breast, cervical, and
colorectal cancer screening determined that there is insufficient
evidence to support  use of these media (11).  More research is
needed to evaluate the efficacy of mass media in promoting can-
cer screening, which may be difficult because mass media are of-
ten  used  in  combination  with  other  interventions  to  promote
screening.
Screening provision
Only 6 of the 12 nongrantees that reported providing screening re-
ported  that  they  had  funding  allocated  specifically  for  CRC
screening. The other 6 grantees may have used more general funds
to provide CRC screening or were able to support screening in
other ways. Not surprisingly, because they had dedicated CDC
funding for CRC screening, CRCCP grantees were significantly
more likely than nongrantees to provide that screening and were
more engaged in recruiting patients for screening. About half of
the grantees provided either fecal occult blood testing or fecal im-
munochemical testing as their primary screening test,  and half
provided colonoscopy.
For  the  time  period  surveyed,  July  2011  through  June  2012,
CRCCP grantees provided a total of 12,669 CRC screening tests,
including a combined 6,877 fecal occult blood tests and fecal im-
munochemical tests, 5,680 screening colonoscopies, and 112 sig-
moidoscopies. Nationally, colonoscopy use has significantly in-
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creased over the past decade while screening via stool tests has de-
clined (20,21). The National Colorectal Cancer Roundtable and
others argue for increased use of stool tests given the higher cost
and limited availability of colonoscopy (22). Recognizing that pa-
tients have preferences about test type, CDC recommends that
health care providers identify and offer the tests that their patients
will be most likely to complete (4).
Limitations
We do not have information on nongrantees that did not respond
to the survey, and it is possible that responders were more likely to
be involved in CRC activities than nonresponders. If this is the
case, our findings would underestimate the effect of CRCCP fund-
ing on screening promotion and provision of nongrantees com-
pared with grantees. Also, respondents may not have been aware
of all CRC activities in their states or tribes. Both CRCCP grantees
and nongrantees have a range of resources for CRC screening, but
grantees reported on only CDC-funded CRC screening promotion
and provision activities. All information reported here is based on
an administrator’s assessment of the program and was not verified
by actual data. Because we have no data on use of evidence-based
interventions before CRCCP funding, we cannot exclude the pos-
sibility that use of the interventions may have been higher among
CRCCP grantees than among nongrantees at baseline. However,
the large differences in use of these interventions between the 2
groups and the lack of differences in the use of other interventions
support our conclusions.
Conclusions
Given limited program resources, the total number of screening
tests provided through the CRCCP is relatively small; however,
given their low income and lack of adequate insurance, the people
screened would probably have remained unscreened were it not
for  CRCCP.  CRCCP grantees  were  more  likely  to  implement
evidence-based interventions promoting CRC screening than non-
grantees,  suggesting that  CRCCP funding and support  can in-
crease use of  evidence-based interventions.  Both groups were
equally likely to promote CRC screening in other ways. Our eval-
uators will continue to monitor CRC screening rates as well as
CRC incidence and mortality in communities served by CRCCP
grantees and compare the rates and incidence with those in com-
munities served by nongrantees to assess the effect of evidence-
based interventions at the population level.
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Tables
Table 1. Comparison of States With or Without Grants for a Colorectal Cancer Control Program (CRCCP) Prior to Program Initiation
(2009)
State Characteristics
States with
CRCCP Grants
(N = 25)
States Without
CRCCP Grants
(N = 18)
P Valuean (%) n (%)
Area, sq m (23)
<42,774 6 (24.0) 8 (44.4)
.2442,774 to 71,300 6 (24.0) 5 (27.8)
>71,300 13 (52.0) 5 (27.8)
Population (23)
<2,790,136 7 (28.0) 7 (38.9)
.802,790,136 to 6,044,171 9 (36.0) 5 (27.8)
>6,044,171 9 (36.0) 6 (33.3)
Percentage of population with income below federal poverty level (24)
<13.5% 8 (32.0) 6 (33.3)
.0313.5% to 17.0% 10 (40.0) 4 (22.2)
>17.0% 7 (28.0) 8 (44.4)
Percentage of population aged 18–64 y that is uninsured (25)
<17.5% 8 (47.1) 0 (0)
.0317.5% to 22.9% 4 (23.5) 5 (45.5)
>22.9% 5 (29.4) 6 (54.5)
Percentage of population aged 50–75 y up-to-date with CRC screening (26)
<61.8% 4 (16.0) 7 (38.9)
.0161.8% to 67.4% 9 (36.0) 7 (38.9)
>67.4% 12 (48.0) 4 (22.2)
Have CDC funding for CRC awareness and advocacy activities (27) 9 (36.0) 6 (33.3) .25
Have population-based CRC screening programsb (27) 11 (44.0) 10 (55.6) .18
Have mandated insurance coverage for CRC screening (27) 13 (52.0) 13 (72.2) .11
Participate in Dialogue for Action stakeholder meetings or CRC Capacity
Study (27)
16 (64.0) 9 (50.0) .16
Abbreviations: CRC, colorectal cancer; CDC, Centers for Disease Control and Prevention.
a P values are based on Fisher exact test.
b May not be statewide.
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Table 2. Interventions to Promote Colorectal Cancer Screening Used by Colorectal Cancer Control Program (CRCCP) Grantees and
Nongrantees (N = 24), July 2011–June 2012
Intervention
CRCCP
Granteesa (N
= 29)
Non-
Granteesa
(N – 24) P Valueb
No. of Community Guide-recommended interventionsc used, mean (SD) 3.14 (1.41) 1.25 (1.33) <.001
Small media 28 (97) 12 (50) <.001
Client reminders 22 (76) 5 (21) <.001
Reducing administrative and other structural barriers 17 (59) 6 (25) .01
Provider assessment and feedback 13 (45) 3 (13) .008
Provider reminders 11 (38) 4 (17) .08
Other interventions in use or planned  for next 12 months
Patient navigation for CRC screening promotion 21 (72) 4 (17) <.001
Mass media 15 (52) 10 (42) .48
Provider education, professional development, including physician-to-physician education 12 (41) 9 (37) .78
Quality assurance, quality improvement, including academic detailing, performance
monitoring
8 (28) 7 (29) .90
Group education 7 (24) 6 (25) .97
One-on-one education 5 (17) 5 (21) .75
Client or provider incentives 4 (14) 4 (17) .78
Other 5 (17) 3 (13) .64
Abbreviations: CRC, colorectal cancer; SD, standard deviation.
a Values are n and % unless otherwise indicated.
b P values are based on χ2 test for categorical variables or 2-sample t test for continuous variables.
c www.thecommunityguide.org
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Table 3. Interventions Used by Colorectal Cancer Control Program (CRCCP) Grantees (N = 29) and Nongrantees (N = 24) to Pro-
mote Colorectal Cancer Screening, July 2011–June 2012
Intervention
CRCCP Grantees,
n (%)
Non-Grantees, n
(%) P Valuea
Provides any CRC screening test 29 (100) 12 (50) <.001
Primary screening test provided N=29 N=12 —
Colonoscopy/sigmoidoscopy 13/1 (48) 8/0 (67) .28
High-sensitivity fecal occult blood test or fecal immunochemical test 5/10 (52) 4/0 (33) —
Partners with another organization to provide screening, type of partner
Primary care clinics, excluding federally qualified health centers 20 (69) 5 (42) .11
Endoscopy or gastrointestinal clinics 18 (62) 4 (33) .10
Federally qualified health centers 17 (59) 4 (33) .15
Other 10 (34) 5 (42) .67
Patient navigators support for screening 23 (79) 8 (67) .40
Recruit patients for screening N=29 N=24 —
Brochures 25 (86) 13 (54) .02
Flyers and information posted in clinics, hospitals, or health care
centers
24 (83) 10 (42) .002
Pre-reviewing patient records and charts to identify patients eligible for
screening
14 (48) 5 (21) .04
Tailored letters or communication from health care provider 10 (34) 3 (13) .06
Other 10 (34) 4 (17) .14
None 1 (3) 9 (38) .003
Are partners and resources currently supporting treatment for patients with diagnosed CRC?
Yes 26 (90) 12b(50) .17
No 0 (0) 2 (8) —
No patients with diagnosed CRC yet 3 (10) 10 (42) —
Abbreviations: CRCCP, Colorectal Cancer Control Program; CRC, colorectal cancer; —, not calculated.
a P values based on χ2 test.
b Of the 12 sites that supported treatment of diagnosed CRC, 11 provided CRC screening.
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